Insulin resistance, viral load and response to peginterferon and ribavirin in patients with chronic hepatitis C virus infection
We read the article by Moucari et al in Gut recently 1 with great interest. The authors concluded that insulin resistance (IR) is correlated independently with serum hepatitis C virus (HCV)-RNA and frequently encountered in patients with HCV genotype 4 (HCV-4) infection. Also IR is a major predictor of response to peginterferon and ribavirin in 108 HCV-4 patients receiving a 48-week course of peginterferon plus ribavirin.
In our previous study we enrolled 330 Taiwanese patients with chronic hepatitis C (CHC) (150 HCV genotype 1 (HCV-1) and 180 genotype non 1 (HCV-non 1) to evaluate the association between homeostasis model assessment of IR (HOMA-IR) and response to therapy. 2 We checked the association between HOMA-IR and serum HCV-RNA level. The mean serum HCV RNA levels were similar between high HOMA-IR (>2. Moucari et al reported that IR is a major predictor of response to peginterferon and ribavirin in HCV-4 patients, which indeed meets with applause. We have found that HOMA-IR was associated with SVR to peginterferon plus ribavirin in HCV-1 patients, but not in HCV-non 1 patients. Romero-Gomez et al 3 and Conjeevaram et al 4 have also reported the high HOMA-IR impairs the response to combination therapy in HCV-1 patients in different countries and all the studies strengthen the important role of IR on the response to anti-HCV combination therapy in HCV-1 and -4 patients. By the way, the HCV viral load was an independent factor, in addition to HOMA-IR, associated with SVR in HCV-1 2 4 patients. In HCV-4 patients Kamal et al reported that the viral load was highly correlated with and the best predictive marker for peginterferon plus ribavirin responsiveness. 5 It is noteworthy that Moucari et al reported the HOMA-IR rather than the HCV RNA level is a predictor of viral response in HCV-4 patients which minimised the role of pretreatment HCV RNA level on the viral response when taking the HOMA-IR into consideration in HCV-4 patients. 1 We just wonder whether the association between the HOMA-IR and HCV RNA level still exists in these 108 HCV-4 patients? On the other hand, the impact of HOMA-IR on SVR rate was especially discovered among patients with HCV-1 infection and high serum HCV RNA level (defined as 'difficult-to-treat' patients) in our previous study. It seems interesting that whether this finding can also be depicted among the HCV-4 patients in the study of Moucari et al. 
